
Over recent years the UK has pioneered the evolution towards payer-driven healthcare. This has created significant business shifts in both primary and secondary care, provoking a fundamental rethink of pharmaceutical commercial operating and governance models. Now, with its White Paper Equity and Excellence: Liberating the NHS2, the UK Government has signalled yet another revolution in the way healthcare is organised and delivered. Although the intent and underlying principles of the NHS reform set out in the White Paper may be laudable, the reality is likely to present major challenges both to healthcare professionals and to the pharmaceutical industry, with a high risk that the ‘new’ commercial models currently being developed and implemented will no longer be fit for purpose.
Fields marked * are compulsory